Table 3.
Comparison of HPV 16 variant distributions and sequence variations with neighboring districts and countries
| Variant (sample no.) | Reference | No. of cases sequenced | No. (%) of cervical carcinoma casesa |
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HPV 16 variant |
E lineage |
Variation site |
||||||||||||||||||||||
| E | As | Af-1 | Af-2 | AA | NA | E prototype | E variant | D25E in E6 | T350G (L83V) in E6 | G94A in E6 | T178A in E6 | A276G (N58S) in E6 | C335T (H78Y) in E6 | A442C (E113D) in E6 | T183G (I27R) in E6 | A647G (N29S) in E7 | C749T (S63F) in E7 | G666A in E7 | C6826T (silence) in L1 | G7521A in LCR | G7842A in LCR | |||
| Northeast China (1) | 52 | 35 (67.31) | 17 (32.69) | 0 | 0 | 0 | 0 | 19 (54.29) | 16 (45.71) | 22 (42.31) | 3 (5.77) | 6 (11.54) | 5 (9.62) | 2 (3.85) | 0 | 1 (1.92) | 0 | 18 (34.62) | 0 | 20 (38.46) | 17 (36.17) | 51 (98.08) | 16 (30.77) | |
| Southwest China—Sichuan (2) | 35 | 113 | 78 (69.03) | 35 (30.97) | 0 | 0 | 0 | 0 | 26 (33.33) | 52 (66.67) | 35 (30.97) | 35 (30.97) | 7 (6.19) | 0 | 4 (3.54) | 14 (12.39) | 7 (6.19) | 0 | — | — | — | — | — | — |
| Southwest China—Sichuan (3) | 41 | 21 | 16 (76.19) | 5 (23.81) | 0 | 0 | 0 | 0 | 4 (25.00) | 12 (75.00) | 5 (23.81) | 2 (9.52) | 0 | 0 | 0 | 2 (9.52) | 1 (4.76) | 0 | 3 (14.29) | 0 | 3 (14.29) | — | 6 (60.00) | 3 (14.29) |
| Central China—Hubei (4) | 5 | 58 | 23 (39.66) | 35 (60.34) | 0 | 0 | 0 | 0 | 9 (39.13) | 14 (60.87) | 36 (62.07) | 3 (5.17) | — | 1 (1.72) | 0 | 2 (3.45) | 5 (8.62) | 3 (5.17) | — | — | — | — | — | — |
| Central and southern China—Jiangxi, Guangdong (5) | 47 | 55 | 19 (34.55) | 36 (65.45) | 0 | 0 | 0 | 0 | 5 (26.32) | 14 (73.68) | 37 (67.27) | 2 (3.64) | 0 | 1 (1.82) | 0 | 3 (5.45) | 8 (14.55) | 0 | 33 (70.21) | 24 (51.06) | 2 (4.26) | — | — | — |
| Japan (6) | 27 | 43 | 24 (55.81) | 19 (44.19) | 0 | 0 | 0 | 0 | 5 (20.83) | 19 (79.17) | 19 (44.19) | 14 (32.56) | 0 | 0 | 1 (2.33) | 3 (6.98) | 11 (25.58) | 1 (2.33) | — | — | — | — | — | — |
| Northeast Thailand (7) | 10 | 23 | 6 (26.09) | 17 (73.91) | 0 | 0 | 0 | 0 | 1 (16.67) | 5 (83.33) | 17 (73.9) | — | 0 | 0 | — | — | — | — | — | — | — | — | — | — |
| Russia (8) | 19 | 32 | 30 (93.75) | 0 | 0 | 0 | 0 | 2 (6.25) | 5 (16.67) | 25 (83.33) | 0 | 27 (84.38) | 0 | 0 | 0 | 2 (6.25) | 0 | 0 | — | — | — | — | — | — |
| Indonesia (9) | 11 | 22 | 19 (86.36) | 2 (9.09) | 0 | 1 (4.55) | 0 | 0 | 7 (36.84) | 12 (63.16) | 2 (9.09) | 1 (4.55) | 0 | 0 | 9 (40.91) | 1 (4.55) | 0 | 0 | 5 (22.73) | 0 | 16 (72.73) | 17 (77.27) | — | — |
| North India (10) | 32 | 60 | 52 (86.67) | 0 | 0 | 0 | 2 (3.33) | 6 (10.00) | 18 (34.62) | 34 (65.38) | 0 | 42 (70.00) | 0 | 0 | 0 | 6 (10.00) | 0 | 0 | 0 | 0 | 1 (1.67) | 0 | 41 (68.33) | 0 |
a
A dash indicates that no data were provided. Chi-square (χ2) tests were applied in this study. Regarding HPV 16 variant distribution, the differences had no significance between samples 1 and 2, 1 and 3, 2 and 3, 1 and (2 + 3), 4 and 5, and 1 and 6 (P value > 0.05), while statistical significance existed between samples 1 and 4/5/7/8/9/10, 1 and (4 + 5), (2 + 3) and 6/7/8/9/10, and (4 + 5) and 6/7/8/9/10 (P value < 0.05). Regarding the distribution of the HPV 16 European prototype and European variant, statistical significance existed between 1 and 2/3/4/5/6/7/8/9/10.